RecruitingNot ApplicableNCT06346080

Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment


Sponsor

KU Leuven

Enrollment

2,200 participants

Start Date

Aug 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this survey is to investigate the participants' preference for a specific screening/diagnostic tool to detect and assess gastro-esophageal cancer. The main question it aims to answer are: * Which diagnostic modality is preferred by patients and the general population? * Which features of the diagnostic test are most detrimental in the decision-making for one or the other modality? * Are geographical differences present in regard to the preference for a diagnostic modality? Participants will be asked to complete a survey of 20-25min, including a brief intake regarding their socio-economic status. This approach will allow us to correct for confounding factors.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying what patients prefer when it comes to molecular (genetic) testing options for stomach and esophageal cancers, using an online survey. You may be eligible if... - You are between 18 and 75 years old - You have access to a computer or smartphone - You can understand and read one of these languages: English, French, Dutch, Spanish, German, Chinese, or Japanese You may NOT be eligible if... - You are under 18 or over 75 years old - You are currently incarcerated Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSurvey

Discrete choice survey


Locations(1)

University Hospitals Leuven

Leuven, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06346080


Related Trials